Injecting and HIV prevalence among young heroin users in three Spanish cities and their association with the delayed implementation of harm reduction programmes

Journal of Epidemiology and Community Health

Volumn 60, Issue 6, 2006, Pages 537-542

  De La Fuente, Luis ^a,b   Bravo, María José ^b   Toro, Carlos ^c   Brugal, M Teresa ^d   Barrio, Gregorio ^e   Soriano, Vicente ^c   Vallejo, Fernando ^a   Ballesta, Rosario ^f  

^a CARLOS III INSTITUTE OF HEALTH   (Spain)

^b MINISTERIO DE SANIDAD Y CONSUMO   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^f Fundacion Andaluza para la Atencion a Las Drogodependencias e Incorporacion Social   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE;

DRUG; DRUG USER; EPIDEMIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; FEMALE; HARM REDUCTION; HEALTH CENTER; HEALTH PROGRAM; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION RISK; INJECTION; INTERVIEW; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; SEXUAL BEHAVIOR; SPAIN;

ANDALUCIA; BARCELONA [CATALONIA]; CATALONIA; EURASIA; EUROPE; MADRID [SPAIN]; SEVILLA; SEVILLE; SOUTHERN EUROPE; SPAIN;

EID: 33744492631     PISSN: 0143005X     EISSN: None     Source Type: Journal    
DOI: 10.1136/jech.2005.037333     Document Type: Article

References (25)

1. de la Fuente L, Bravo MJ, Lew C, et al. [The prevalence of human immunodeficiency virus infection and the risk behaviors in the heroin addicts of Barcelona, Madrid and Seville: an example of the advantages of centering studies on addicts and not just on intravenous users]. Med Clin (Barc) 1999;113:646-51.
2. de la Fuente L, Barrio G, Vicente J, et al. Intravenous administration among heroin users having treatment in Spain. Int J Epidemiol 1994;23:805-11.
3. Drucker E, Lurie P, Wodak A, et al. Measuring harm reduction: the effects of needle and syringe exchange programs and methadone maintenance on the ecology of HIV. AIDS 1998;12:5217-30.
4. Gibson DR, Flynn NM, McCarthy JJ. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 1999;13:1807-18.
5. Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 2001;15:1329-41.
6. de la Fuente L, Bravo MJ, Barrio G, et al. Lessons from the history of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic among Spanish drug injectors. Clin Infect Dis 2003;37:S410-15.
7. Domingo-Salvony A, Perez K, Torrens M, et al. Methadone treatment in Spain, 1994. Drug Alcohol Depend 1999;56:61-6.
8. Des Jarlais DC, Hammett TM, Wei L, et al. Opiate agonist maintenance treatment for injecting drug user peer educators. Addiction 2004;99:1355-6.
9. Moshkova A. Substitution therapy: overcoming ignorance. Horm Reduction News 2003;4:1-1.
10. Barrio G, de la Fuente L, Royuela L, et al. Cocaine use among heroin users in Spain: the diffusion of crack and cocaine smoking. Spanish Group for the Study on the Route of Administration of Drugs. J Epidemiol Community Health 1998;52:172-80.
11. de la Fuente L, Barrio G, Royuela L, et al. The transition from injecting to smoking heroin in three Spanish cities. The Spanish Group for the Study of the Route of Heroin Administration. Addiction 1997;92:1749-63.
12. de la Fuente L, Brugal MT, Ballesta R, et al. Metodología del estudio de cohortes del proyecto Itinere sobre consumidores de heroína en tres ciudades españolas y características básicas de los participantes [Cohort study methodology of the ITINERE project on heroin users in three Spanish cities and main characteristics of the participants]. Rev Esp Salud Pública 2005;79:475-91.
13. Watters JK, Biernacki P. Targeted sampling: options for the study of hidden populations. Social Problems 1989;36:416-30.
14. Heckathorn DD. Respondent -driven sampling: a new approach to the study of hidden populations. Social Problems 1997;44:174-9.
15. Centre de Estudis Epidemiològics sobre la Sida de Catalunya. CESCAT. Les Programmes d'ëchange de Seringes pour la Prévention du HIV dans les pays du Sud de l'Europe.PESESUD 1997. In: Barcelona 1998. Barcelona, CESCAT, 2004.
16. Welp EA, Lodder AC, Langendam MW, et al. HIV prevalence and risk behaviour in young drug users in Amsterdam. AIDS 2002;16:1279-84.
17. Tyndall MW, Currie S, Spittal P, et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS 2003;17:887-93.
18. Paredes D, Del Llano J, Ruiz M. Estimación de la prevalencia de la adicción a la heroína en la Comunidad de Madrid durante 1992. Madrid: Comunidad de Madrid, 1992.
19. Domingo-Salvany A, Hartnoll RL, Maguire A, et al. Analytical considerations in the use of capture-recapture to estimate prevalence: case studies of the estimation of opiate use in the metropolitan area of Barcelona, Spain. Am J Epidemiol 1998;148:732-40.
20. Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet 1997;349:1797-800.
21. Toro C, Brugal MT, Vallejo F, et al. Incidencia de infección por VIH en los jóvenes consumidores de heroína (inyectores y no inyectores) de Madrid y Barcelona (PROYECTO ITÍNERE) [Incidence of HIV infection among young heroin users (injecting and non-injecting) from Madrid, Barcelona and Seville (ITINERE PROJECT). Sociedad Española Interdisciplinaria del Sida. VIII Congreso Nacional sobre el Sida, Madrid, 2004.
22. de la Fuente L, Saavedra P, Barrio G, et al. Temporal and geographic variations in the characteristics of heroin seized in Spain and their relation with the route of administration. Drug Alcohol Depend 1996;40:185-94.
23. Garfein RS, Monterroso ER, Tong TC, et al. Comparison of HIV infection risk behaviors among injection drug users from East and West Coast US cities. J Urban Health 2004;81:260-7.
24. Clatts MC, Heimer R, Abdala N, et al. HIV-1 transmission in injection paraphernalia: heating drug solutions may inactivate HIV-1. J Acquir Immune Defic Syndr 1999;22:194-9.
25. United Nations. Joint United Nations Programme on HIV/AIDS. Report on the global HIV/AIDS epidemic 2002. Geneva: UNAIDS, 2002.